Relugolix Nitroso Impurity 1

Status: Under Development

It is one of impurity present in Relugolix, Relugolix is a gonadotropin-releasing hormone receptor antagonist, Cytochrome P450 3A Inducer, and Cytochrome P450 2B6 Inducer and Breast Cancer Resistance Protein Inhibitor, and P-Glycoprotein Inhibitor. the physiologic effect of relugolix is using Decreased GnRH Secretion. which is used for androgen deprivation therapy in the treatment of advanced prostate cancer.

Contact us

Additional information on Relugolix Nitroso Impurity 1

Catalogue No. VE009886
Molecular Formula C28H24F2N8O6S
Molecular Weight 638.6 g/mol
Parent drug Relugolix
IUPAC Name 1-(4-(1-(2, 6-difluorobenzyl)-3-(6-methoxypyridazin-3-yl)-5-((methyl(nitroso)amino)methyl)-2, 4-dioxo-1, 2, 3, 4-tetrahydrothieno[2, 3-d]pyrimidin-6-yl)phenyl)-3-methoxyurea
Synonyms N/A
References Saad, F., & Shore, N. D. (2021). Relugolix: a novel androgen deprivation therapy for management of patients with advanced prostate cancer. Therapeutic Advances in Medical Oncology, 13, 175883592199858.
Status Under Development

Request a quote

We Respond Within a Few Hours - Whether You're a New or Existing Client

Payment Made Simple: All major Credit/Debit cards accepted

Streamlined 3-Step Process from Quotes to Orders:

Product name:

Relugolix Nitroso Impurity 1

"*" indicates required fields

Products quotation
This field is for validation purposes and should be left unchanged.